Collaborative researcher will be presenting at CD1-MR1 2024

Tokyo, Japan - February 20, 2024/ -- BrightPath Biotherapeutics (TSE Growth 4594), a clinical- stage biopharmaceutical company focused on developing novel immunotherapeutics, announced that a collaborative researcher on iPS cell-derived NKT cell therapy will be presenting at the 13th International CD1-MR1 Conference held in Tasmania, Australia, February 26th to 29th 2024.

Presentation Details:

Presentation Title: Clinical application of iPS cell-derived NKT cells to cancer immunotherapy
Speaker: Shinichiro Motohashi, MD, Ph.D, Professor, Department of Medical Immunology, Graduate School of Medicine, Chiba University
Presentation Date and Time: February 29th, 9:25 - 9:45 a.m. AEDT

About CD1-MR12024:
The meeting will highlight the immune surveillance axis surrounding the MHC-I-like molecules CD1 and MR1 and unconventional T cells, such as natural killer T (NKT) cells and mucosal-associated invariant T (MAIT) cells. Discussions will span the latest research from CD1 and MR1 antigen presenting molecules, fundamental biology of the unconventional T cells, such as the antigens they recognize, their development, and diverse functions in health and disease, and explore therapeutic strategies that target this axis.

CD1-MR1 2024
https://www.cd1mr1.com/